Drugs / FOLFOX6
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02243358 | Feb 2014 → Jun 2017 | malignant pancreatic neoplasm | Henry Ford Health System | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01605305 Background | Sep 2008 → Jan 2012 | esophageal squamous cell carcinoma | Fudan University | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2010-11-18 | AVEO Pharmaceuticals, Inc. | AVEO’s Tivozanib in Combination with FOLFOX6 Demonstrates Anti-tumor Activity and Safety in Advanced GI Cancers; Results Presented at EORTC-NCI-AACR Symposium aveooncology.com ↗ |
| 2010-11-10 | AVEO Pharmaceuticals, Inc. | AVEO to Present New Clinical Data Evaluating Tivozanib in Combination with FOLFOX6 at EORTC-NCI-AACR Symposium aveooncology.com ↗ |
| 2008-08-25 | AVEO Pharmaceuticals, Inc. | AVEO Initiates Phase 1b Combination Trial of AV-951 with FOLFOX6 in Patients with Advanced Colorectal and Other Gastrointestinal Cancers aveooncology.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Folfox6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02243358 ↗ |
| Route | Intravenous | “LV 400mg/m2 ivgtt 2h d1” NCT01605305 ↗ |